OsteosarcomaBOOSTNCT03225872
Biology of Osteosarcoma (BOOST) Registry and Biobank
An observational study of Osteosarcoma, run by University of Minnesota at 1 site in United States.
Trial summary
Osteosarcoma is very rare cancer of the bone. The investigator started the BOOST registry and biobank to make sure every patient has the opportunity to participate in research. Read more about this study
- Who is it for?
- Ages 0 years and olderHealthy volunteers can take part
- Conditions the study is for
- Osteosarcoma
- How many people
- 362 participants
- Where
- 1 siteUnited States
- Study dates
- 3 Jan 2017to 27 Jan 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Worldwide
Who may be able to join
- Proband Inclusion criteria: A diagnosis or suspected diagnosis of osteosarcoma (ICCC 9180-9200)
- Family member inclusion criteria: Biological parents and full biological siblings of a case diagnosed with osteosarcoma (ICCC 9180-9200)
Who cannot join
- Does not understand English.
Trial locations and contacts
1 site in 1 country.
About this study
Osteosarcoma is very rare cancer of the bone. The investigator started the BOOST registry and biobank to make sure every patient has the opportunity to participate in research.
Read the detailed description
Summary to include:
- Samples of saliva, blood and/or other stored material such as slides or leftover diagnostic material. If available the investigator may ask you for deciduous (baby) teeth.
- Questionnaire information, including health history, growth and development, physical activity and family medical history information.
- If you have been diagnosed with a osteosarcoma or another condition the investigator is interested inthe investigator will ask you release medical record information relating to diagnosis and treatment of osteosarcoma, other cancers, blood disorders, and similar conditions. If this step applies to you then you will be asked to sign a separate form.
- You may be asked to contact your biological parents and full biological siblings to ask them about participating in the study.
- If you agree you may be contacted in the future. You will be able to decline any future information or studies at any point.
- Conditions
- Osteosarcoma
- Keywords
- Osteosarcoma, Bone cancer, Family-based study
- Medical subject headings
- Osteosarcoma, Bone Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Osteosarcoma patients and family members | Osteosarcoma patients and family members |
What is being measured
The primary outcome is the main question the study is designed to answer.
Determine if genes can determine osteosarcoma
To do this the investigator will compare the genes of people with osteosarcoma to the genes of people who do not have these conditions.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jul 2017
- Study start3 Jan 2017
- Primary completion27 Jan 2020
- Study completion27 Jan 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OsteosarcomaStudies of the same condition, open and under way.
- More trials run by University of MinnesotaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Family based
- Time perspective
- Retrospective
- Enrolment
- 362 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Minnesota
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Logan G. Spector, PhD, Principal investigator, University of Minnesota
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03225872
- Sponsor's protocol ID
- 2016NTLS073
- Acronym
- BOOST
- Status last verified
- Nov 2025
- First submitted
- 19 Jul 2017
- Last updated
- 2 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Biology of Osteosarcoma (BOOST) Registry and Biobank
- ClinicalTrials.gov ID
- NCT03225872
- Acronym / sponsor ID
- BOOST / 2016NTLS073
- Conditions
- Osteosarcoma
- Keywords
- Osteosarcoma, Bone cancer, Family-based study
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 362 participants (actual)
- Lead sponsor
- University of MinnesotaUniversity, hospital or other
- Study start
- 3 Jan 2017 (actual)
- Primary completion
- 27 Jan 2020 (actual)
- Study completion
- 27 Jan 2020 (actual)
- First posted
- 21 Jul 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Osteosarcoma is very rare cancer of the bone. The investigator started the BOOST registry and biobank to make sure every patient has the opportunity to participate in research.
Detailed description
Summary to include:
- Samples of saliva, blood and/or other stored material such as slides or leftover diagnostic material. If available the investigator may ask you for deciduous (baby) teeth.
- Questionnaire information, including health history, growth and development, physical activity and family medical history information.
- If you have been diagnosed with a osteosarcoma or another condition the investigator is interested inthe investigator will ask you release medical record information relating to diagnosis and treatment of osteosarcoma, other cancers, blood disorders, and similar conditions. If this step applies to you then you will be asked to sign a separate form.
- You may be asked to contact your biological parents and full biological siblings to ask them about participating in the study.
- If you agree you may be contacted in the future. You will be able to decline any future information or studies at any point.
Study design
- Observational model
- Family based
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Osteosarcoma patients and family members | – | –Osteosarcoma patients and family members |
Who may qualify
- Ages
- 0 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Worldwide
Key inclusion criteria (2 listed)
- Proband Inclusion criteria: A diagnosis or suspected diagnosis of osteosarcoma (ICCC 9180-9200)
- Family member inclusion criteria: Biological parents and full biological siblings of a case diagnosed with osteosarcoma (ICCC 9180-9200)
Key exclusion criteria (1 listed)
- Does not understand English.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Determine if genes can determine osteosarcoma
Time frame: Baseline
To do this the investigator will compare the genes of people with osteosarcoma to the genes of people who do not have these conditions.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Dec 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Osteosarcoma
RecruitingPhase 1/2
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma
RecruitingObservational study
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Pheochromocytoma, Paraganglioma
RecruitingPhase 2
Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma
Osteogenic Sarcoma Recurrent
RecruitingPhase 2
The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
RecruitingPhase 2
Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma
Pediatric Osteosarcoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Logan G. Spector, PhD principal investigator
University of Minnesota
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Osteosarcoma, run by University of Minnesota at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Determine if genes can determine osteosarcoma (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2025.